GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dendreon Corp (FRA:DNR) » Definitions » E10

Dendreon (FRA:DNR) E10 : €-1.68 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Dendreon E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Dendreon's adjusted earnings per share data for the three months ended in Sep. 2014 was €-0.109. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.68 for the trailing ten years ended in Sep. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-17), Dendreon's current stock price is €0.13. Dendreon's E10 for the quarter that ended in Sep. 2014 was €-1.68. Dendreon's Shiller PE Ratio of today is .


Dendreon E10 Historical Data

The historical data trend for Dendreon's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dendreon E10 Chart

Dendreon Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.27 -1.37 -1.56 -1.67 -

Dendreon Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Mar15
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.67 -1.69 -1.70 -1.68 -

Competitive Comparison of Dendreon's E10

For the Biotechnology subindustry, Dendreon's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dendreon's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dendreon's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Dendreon's Shiller PE Ratio falls into.



Dendreon E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dendreon's adjusted earnings per share data for the three months ended in Sep. 2014 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-0.109/100.4278*100.4278
=-0.109

Current CPI (Sep. 2014) = 100.4278.

Dendreon Quarterly Data

per share eps CPI Adj_EPS
200412 -0.275 80.290 -0.344
200503 -0.250 81.555 -0.308
200506 -0.247 82.062 -0.302
200509 -0.270 83.876 -0.323
200512 -0.338 83.032 -0.409
200603 -0.283 84.298 -0.337
200606 -0.205 85.606 -0.240
200609 -0.228 85.606 -0.267
200612 -0.215 85.142 -0.254
200703 -0.287 86.640 -0.333
200706 -0.201 87.906 -0.230
200709 -0.165 87.964 -0.188
200712 -0.223 88.616 -0.253
200803 -0.148 90.090 -0.165
200806 -0.116 92.320 -0.126
200809 -0.202 92.307 -0.220
200812 -0.069 88.697 -0.078
200903 -0.123 89.744 -0.138
200906 -0.857 91.003 -0.946
200909 -0.274 91.120 -0.302
200912 -0.191 91.111 -0.211
201003 -0.708 91.821 -0.774
201006 -0.851 91.962 -0.929
201009 -0.427 92.162 -0.465
201012 -0.487 92.474 -0.529
201103 -0.556 94.283 -0.592
201106 -0.548 95.235 -0.578
201109 -0.727 95.727 -0.763
201112 0.198 95.213 0.209
201203 -0.530 96.783 -0.550
201206 -0.518 96.819 -0.537
201209 -0.807 97.633 -0.830
201212 -0.197 96.871 -0.204
201303 -0.371 98.209 -0.379
201306 -0.341 98.518 -0.348
201309 -0.329 98.790 -0.334
201312 -0.425 98.326 -0.434
201403 -0.174 99.695 -0.175
201406 -0.074 100.560 -0.074
201409 -0.109 100.428 -0.109

Add all the adjusted EPS together and divide 10 will get our e10.


Dendreon  (FRA:DNR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Dendreon E10 Related Terms

Thank you for viewing the detailed overview of Dendreon's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Dendreon (FRA:DNR) Business Description

Traded in Other Exchanges
N/A
Address
Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.

Dendreon (FRA:DNR) Headlines

No Headlines